Corton Capital Inc. Increases Stock Position in Alphatec Holdings, Inc. $ATEC

Corton Capital Inc. boosted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 36.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,157 shares of the medical technology company’s stock after buying an additional 5,097 shares during the quarter. Corton Capital Inc.’s holdings in Alphatec were worth $213,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Bank of Montreal Can boosted its position in Alphatec by 545.7% during the 2nd quarter. Bank of Montreal Can now owns 743,041 shares of the medical technology company’s stock valued at $8,248,000 after acquiring an additional 627,973 shares in the last quarter. Emerald Advisers LLC lifted its stake in shares of Alphatec by 3.8% during the 2nd quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company’s stock worth $18,696,000 after purchasing an additional 60,885 shares during the last quarter. Motley Fool Wealth Management LLC boosted its position in Alphatec by 21.0% during the second quarter. Motley Fool Wealth Management LLC now owns 1,082,670 shares of the medical technology company’s stock valued at $12,018,000 after purchasing an additional 188,199 shares in the last quarter. Teacher Retirement System of Texas grew its stake in Alphatec by 12.3% in the second quarter. Teacher Retirement System of Texas now owns 17,447 shares of the medical technology company’s stock valued at $194,000 after purchasing an additional 1,912 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Alphatec by 22.4% in the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Sponsel sold 70,000 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $16.18, for a total transaction of $1,132,600.00. Following the sale, the executive vice president directly owned 461,861 shares of the company’s stock, valued at approximately $7,472,910.98. This represents a 13.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Scott Lish sold 6,323 shares of the firm’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $16.01, for a total transaction of $101,231.23. Following the sale, the chief operating officer owned 658,707 shares in the company, valued at approximately $10,545,899.07. This represents a 0.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 788,125 shares of company stock worth $12,604,027. Corporate insiders own 22.80% of the company’s stock.

Alphatec Trading Up 0.7%

Shares of Alphatec stock opened at $19.42 on Wednesday. The stock has a market cap of $2.88 billion, a PE ratio of -17.19 and a beta of 1.17. The firm has a fifty day moving average price of $15.41 and a 200 day moving average price of $13.41. Alphatec Holdings, Inc. has a 1 year low of $7.87 and a 1 year high of $20.15. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. The business’s quarterly revenue was up 30.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Needham & Company LLC raised their target price on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Barclays lifted their price target on shares of Alphatec from $22.00 to $23.00 and gave the stock an “overweight” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alphatec in a report on Tuesday, October 14th. Finally, Stifel Nicolaus initiated coverage on Alphatec in a research note on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price target for the company. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.